GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entero Therapeutics Inc (FRA:366) » Definitions » Deferred Policy Acquisition Costs

Entero Therapeutics (FRA:366) Deferred Policy Acquisition Costs


View and export this data going back to 2018. Start your Free Trial

What is Entero Therapeutics Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Entero Therapeutics (FRA:366) Business Description

Industry
Traded in Other Exchanges
Address
777 Yamato Road, Suite 502, Boca Raton, FL, USA, 33431
First Wave BioPharma Inc is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical-stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.